Publication Cover
Redox Report
Communications in Free Radical Research
Volume 11, 2006 - Issue 3
387
Views
12
CrossRef citations to date
0
Altmetric
Research articles

Ursodeoxycholic acid in primary biliary cirrhosis improves glutathione status but fails to reduce lipid peroxidation

, , &
Pages 117-123 | Published online: 19 Jul 2013

References

  • Poupon RE, Balkau B, Eschwege E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991; 324: 1548–1554.
  • Goulis J, Leandro G, Burroughs AK. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999; 354: 1053–1060.
  • Corpechot C, Carrat F, Bahr A, Chretien Y, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005; 128: 297–303.
  • Schmucker DL, Ohta M, Kanai S, Sato Y, Kitani K. Hepatic injury induced by bile salts: correlation between biochemical and morphological events. Hepatology 1990; 12: 1216–1221.
  • Trauner M, Graziadei IW. Mechanisms of action and therapeuticapplications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther 1999; 13: 979–996.
  • Lazaridis KN, Gores GJ, Lindor KD. Ursodeoxycholic acid ‘mechanisms of action and clinical use in hepatobiliary disorders’. J Hepatol 2001; 35: 134–146.
  • Marteau P, Chazouilleres O, Myara A, Ran R, Rambaud JC, Poupon R. Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man. Hepatology 1990; 12: 1206–1208.
  • Rodrigues CM, Steer CJ. Mitochondrial membrane perturbations in cholestasis. J Hepatol 2000; 32: 135–141.
  • Calmus Y, Gane P, Rouger P, Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990; 11: 12–15.
  • Sokol RJ, Straka MS, Dahl R et al. Role of oxidant stress in the permeability transition induced in rat hepatic mitochondria by hydrophobic bile acids. Pediatr Res 2001; 49: 519–531.
  • Yerushalmi B, Dahl R, Devereaux MW, Gumpricht E, Sokol RJ. Bile acid-induced rat hepatocyte apoptosis is inhibited by antioxidants and blockers of the mitochondrial permeability transition. Hepatology 2001; 33: 616–626.
  • Ljubuncic P, Fuhrman B, Oiknine J, Aviram M, Bomzon A. Effect of deoxycholic acid and ursodeoxycholic acid on lipid peroxidation in cultured macrophages. Gut 1996; 39: 475–478.
  • Sreejayan N, von Ritter C. Effect of bile acids on lipid peroxidation: the role of iron. Free Radic Biol Med 1998; 25: 50–56.
  • Lapenna D, Ciofani G, Festi D et al. Antioxidant properties of ursodeoxycholic acid. Biochem Phannacol 2002; 64: 1661–1667.
  • Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol 2001; 35: 297–306.
  • Jain SK, Pemberton PW, Smith A et al. Oxidative stress in chronic hepatitis C: not just a feature of late stage disease. J Hepatol 2002; 36: 805–811.
  • Pemberton PW, Aboutwerat A, Smith A, Burrows PC, McMahon RF, Warnes TW. Oxidant stress in type I autoimmune hepatitis: the link between necroinflammation and fibrogenesis? Biochim Biophys Acta 2004; 1689: 182–189.
  • Pemberton PW, Smith A, Warnes TW. Non-invasive monitoring of oxidant stress in alcoholic liver disease. Scand J Gastroenterol 2005; 40: 1102–1108.
  • Aboutwerat A, Pemberton PW, Smith A et al. Oxidant stress is a significant feature of primary biliary cirrhosis. Biochim Biophys Acta 2003; 1637: 142–150.
  • Warnes TW, Smith A, Lee Fl, Haboubi NY, Johnson PJ, Hunt L. A controlled trial of colchicine in primary biliary cirrhosis. J Hepatol 1987; 5: 1–7.
  • Shapiro JM, Smith H, Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 1979; 20: 137–140.
  • Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646–649.
  • Whitehead TP, Thorpe GH, Maxwell SR. Enhanced chemiluminescent assay for antioxidant capacity in biological fluids. Anal Chim Acta 1992; 266: 265–277.
  • Sies H, Akerboom TP. Glutathione disulfide (GSSG) efflux from cells and tissues. Methods Enzymol 1984; 105: 445–451.
  • Babbs C, Smith A, Hunt LP, Rowan BP, Haboubi NY, Warnes TW. Type III procollagen peptide: a marker of disease activity and prognosis in primary biliary cirrhosis. Lancet 1988; 1: 1021–1024.
  • Serviddio G, Pereda J, Pallardo FV et al. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress. Hepatology 2004; 39: 711–720.
  • Mato JM, Camara J, Fernandez de Paz J et al. 5-adenosyl-methionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. J Hepatol 1999; 30: 1081–1089.
  • Akerboom TP, Sies H. Assay of glutathione, glutathione disulfide, and glutathione mixed disulfides in biological samples. Methods Enzymol 1981; 77: 373–382.
  • Lu SC. Regulation of hepatic glutathione synthesis: current concepts and controversies. FASEB J1999; 13: 1169-1183.
  • Rodriguez-Ortigosa CM, Cincu RN, Sanz S, Ruiz F, Quiroga J, Prieto J. Effect of ursodeoxycholic acid on methionine adenyltransferase activity and hepatic glutathione metabolism in rats. Gut 2002; 50: 701–706.
  • Mitsuyoshi H, Nakashima T, Sumida Yet al. Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun 1999; 263: 537–542.
  • Hirata E, Inoue M, Morino Y. Mechanism of biliary secretion of membranous enzymes: bile acids are important factors for biliary occurrence of gamma-glutamyltransferase and other hydrolases. J Biochem (Tokyo) 1984; 96: 289–297.
  • Mates JM, Perez-Gomez C, Blanca M. Chemical and biological activity of free radical ‘scavengers’ in allergic disease. Clin Chim Acta 2000; 296: 1–15.
  • Roberts LJ, Morrow JD. The generation and actions of isoprostanes. Biochim Biophys Acta 1997; 1345: 121–135.
  • van Hoogstraten HJ, Hansen BE, van Buuren HR, ten Kate F, van Berge-Henegouwen GP, Schalm SW. Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. J Hepatol 1999; 31: 256–262.
  • Poli G. Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med 2000; 21: 49–98.
  • Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest 1995; 96: 2461–2468.
  • Gluud C, Christensen E. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst Rev 2002; 1: CD000551.
  • Corpechot C, Carrat F, Bonnand AM, Poupon RE, Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000; 32: 1196–1199.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.